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How human immunodeficiency virus voluntary testing can
contribute to tuberculosis control
Peter Godfrey-Faussett,1 DermotMaher,2 Ya Diul Mukadi,3 Paul Nunn,2 Joseph Perrie¨ns,4 &Mario Raviglione2
Abstract Human immunodeficiency virus (HIV) is fuelling the tuberculosis (TB) epidemic, particularly in sub-Saharan Africa. However,
despite their close epidemiological links, the public health responses have largely been separate. WHO has set out a strategy to decrease
the burden of HIV-related TB, comprising interventions against both TB and HIV. Voluntary counselling and testing (VCT) for HIV can link TB
and HIV programme activities. The benefits of VCT for HIV to TB patients include referral for appropriate clinical care and support for those
testing HIV-positive. Likewise, people attending a centre for VCT can benefit from TB screening: those found to be both HIV-positive and
with active TB need referral for TB treatment; those without active TB should be offered TB preventive treatment with isoniazid.
To explore how VCT for HIV can contribute to a more coherent response to TB, WHO is coordinating the ProTEST Initiative. The
name ‘‘ProTEST’’ is derived from the Promotion of voluntary testing as an entry point for access to the core interventions of intensified
TB case-finding and isoniazid preventive treatment. Other interventions may be added to provide finally a comprehensive range of HIV
and TB prevention and care interventions. Under the ProTEST Initiative, pilot districts are establishing links between centres for VCT for
HIV and TB prevention and care. This will pave the way for large-scale operationalization of the comprehensive range of interventions
needed to control TB in settings with high HIV prevalence.
Keywords Tuberculosis, Pulmonary/prevention and control/epidemiology/diagnosis; AIDS serodiagnosis; Counseling; Volition; AIDS-
related opportunistic infections/prevention and control; HIV seroprevalence; Delivery of health care, Integrated; Cost of illness; Pilot
projects; Africa South of the Sahara (source: MeSH, NLM ).
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Introduction
The human immunodeficiency virus (HIV) pandemic is the
world’s leading public health emergency, with a particularly
severe impact on sub-Saharan Africa. It is destroying the health
of Africans, the economies of African nations and their
prospects for development. HIV infection is also fuelling the
tuberculosis (TB) epidemic, but TB programmes have focused
on TB case-finding and treatment, with little attention toHIV/
AIDS interventions. Although TB is a leading cause of HIV-
relatedmorbidity andmortality, HIV/AIDS programmes have
generally paid little attention to TB. Thus, despite close
epidemiological links between HIV and TB, the public health
responses have largely been separate.
WHO has developed an expanded strategy to decrease
the burden of HIV-related TB, requiring close collaboration
between TB andHIV programmes (1). The strategy comprises
interventions against TB, including intensified case-finding,
cure and preventive treatment, as well as interventions against
HIV (and therefore indirectly against TB). The latter include
counselling for decreased sexual risk behaviour, provision of
condoms, treatment of sexually transmitted infections,
promotion of safety for intravenous drug users and provision
of highly active antiretroviral treatment. WHO and collaborat-
ing bodies have embarked on ‘‘The ProTEST Initiative’’ as a
starting point at district level for this comprehensive range of
interventions aimed at decreasing the burden of HIV-related
TB. The Initiative promotes HIV voluntary testing as a key to a
more coherent response to TB in high HIV-prevalence
settings, through strengthening links between HIV and TB
programmes and general health services.
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As part of a new approach to TB control in high HIV-
prevalence settings, the rationale for the ProTEST Initiative
needs public debate. This concept paper sets out the rationale
for the Initiative, based on an analysis of the impact of HIV on
TB control, describes the elements of the ProTEST approach,
reviews progress so far and sets out the future direction. The
purpose is to generate discussion and ideas which will help the
Initiative to make a good start in establishing the comprehen-
sive range of interventions needed to control TB in settings
with high prevalence of HIV infection.
Background
TB is a leading cause of death among people living with HIV
(PLWH) (2). About 12 million out of the 36 million HIV-
infected people worldwide at the end of 2000 were co-
infected with Mycobacterium tuberculosis, and 8.4 million (70%)
of those co-infected live in sub-Saharan Africa (3). In
countries with advanced HIV epidemics, particularly those
of sub-Saharan Africa, the majority of TB patients are also
infected with HIV (4).
Largely associated with poverty and an inadequate health
service response, the TB epidemic in sub-Saharan Africa
remained at a relatively constant level until the onset of the
impact of the HIV epidemic in the 1980s (5). Since then, HIV
has caused a rapid increase in the TB epidemic. In HIV-
infected people, HIV promotes progression to active TB in
people with latent or recently acquiredM. tuberculosis infections;
increasing TB cases in HIV-infected people poses an increased
risk of TB transmission to the general community, whether or
not HIV-infected. Fig. 1 shows the trend of cases of TB in sub-
SaharanAfrica (defined as theWHO region of Africa) since the
mid-1980s, with a relatively constant level of cases of TB until
the onset of the impact of the HIV epidemic in the 1980s. The
assumption that the rising trend since the mid-1980s is
attributable to HIV is based on the temporal relation between
the two epidemics and their known biological and epidemio-
logical links.
Escalating TB case-loads in many countries in the region
are outstripping the ability of health services to cope. Despite
the epidemiological links, the public health responses to HIV
and TB have largely been separate, and have so far had little
success in interrupting the sequence of events by which HIV
infection fuels the TB epidemic. Better coordination of HIV
and TB programme activities may lead to more effective
implementation of interventions to decreaseHIV transmission
and the burden of TB.
There is an urgent need, particularly where HIV is
increasing the prevalence of TB, to ensure that all TB patients
have access to effective TB diagnosis and treatment. Failure to
ensure the essential basics of case-finding and treatment in
countries with severe HIV epidemics will result in an increased
burden of TB over the coming decades, including increased
risk of drug resistance (7). In turn, drug resistance (with its
associated increased TB morbidity and mortality) enormously
complicates TB control and increases its costs (8).
Because of the impact of HIV on the TB epidemic,
additional measures beyond TB case-finding and treatment are
necessary to control TB (1–9). These measures should
complement ongoing efforts to improve specific TB control
tools such as the development of a more effective vaccine (10),
better diagnostic tests (11), better preventive (12) and
therapeutic approaches (13), and more vigorous application
of specific measures to prevent and interrupt transmission in
prisons (14), healthcare institutions (15) and other congregate
settings.
WHO is coordinating the ProTEST Initiative with the aim
of exploring howHIVvoluntary testing can contribute to amore
coherent response to TB in settings with high HIV prevalence.
The core interventions offered to people attending for voluntary
counselling and testing (VCT) for HIV are: intensified TB case-
finding, and isoniazid preventive treatment for those without
active TB. Starting with these core interventions, other
interventions may be added to provide finally a comprehensive
range of HIV and TB prevention and care interventions. Under
the ProTEST Initiative, pilot districts are establishing links
between centres for VCT for HIV and TB prevention and care.
The aim is to derivemutual benefits by promoting VCT for both
improved HIV prevention and care and improved TB control.
This will pave the way for operationalization of the compre-
hensive range of interventions needed to control TB in settings
with high HIV prevalence.
The goal of the ProTEST Initiative is to reduce the
combined burden of TB and HIV through a concerted
approach that will achieve the following objectives: to reduce
the number of people becoming infected with HIV; to reduce
the number of people transmitting bothHIV andM. tuberculosis;
and to reduce the risk of developing active TB in those infected
with both HIV and M. tuberculosis.
Impact of HIV on TB control
Social impact
The stigma and silence surrounding HIV may extend to TB
(already a stigmatized disease in many societies) in commu-
nities which have recognized the link between TB and HIV
(16). Thus the stigma attached to HIV may have an adverse
effect on TB control activities. For example, people may be
frightened to seek a diagnosis for a persistent cough, and try to
avoid standing in a line of TB patients, identifiable by their
neighbours (17).
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Epidemiological impact
Consideration of the basics of TB epidemiology and control
(18) is necessary to understand the impact of HIV. In the
poorer regions of the world, annual risks of infection by
M. tuberculosis are typically 1–3%, leading to prevalence rates of
M. tuberculosis infection among young adults of 30–70% (19).
Fig. 2 is a schematic representation of the impact ofHIVon the
cycle of M. tuberculosis transmission, showing first the situation
in the absence of HIV and then the situation where the HIV
seroprevalence in the general population is 10%.
In the absence of HIV, only about 10% of people infected
with M. tuberculosis will develop active TB (whether from
progression of recent infection or from reactivation), of whom
about one half will be infectious (usually smear-positive) (20).
Thus, only one in 20 people infected withM. tuberculosis develops
infectious TB, and each infectious case in its turn needs to infect
about 20 people in order to generate one further infectious case.
This is the situation of stable TB disease incidence (i.e. the case
reproduction number is one), as shown in panel A of Fig. 2. The
primary stratagem of TB control is to reduce the average
number of people infected by each infectious case so that the
case reproduction number is less than one.
In the presence of HIV infection (the single strongest
risk factor for progression from infection to active disease (21),
about 40% of people infected with M. tuberculosis will develop
active TB in their lifetime (22). Panel B of Fig. 2 shows what
happens to 20 people with M. tuberculosis infection when the
HIV seroprevalence in the population is 10%. There will thus
be 18 HIV-negative and 2 HIV-positive people with M. tu-
berculosis infection.With a 10% risk of developing active TB, the
18 HIV-negative people will generate 1.8 cases of TB. With a
40% risk of developing active TB, the 2 HIV-positive people
will generate 0.8 cases of TB. Although each individual HIV-
positive TB patient may be less infectious (23), each infectious
case now leads to 2.6 new cases, of whom more than one is
infectious. This leads to an expanding epidemic (i.e. the case
reproduction number is more than one).
These simple calculations illustrate the implications of
HIV for TB control. In order to lower the case reproduction
number in the face of the HIV-fuelled TB epidemic, TB
control programmes have not only to detect and cure the
additional cases of HIV-related TB, but also to handle each
case more effectively. This means reducing the average
number of people infected by each case, e.g. by reducing
diagnostic and treatment delays.
Since the mid-1980s, in many African countries,
including those with well-organized programmes (24, 25),
annual TB case notification rates have risen up to fourfold,
reaching peaks of more than 400 cases/100 000 population
(Fig. 3). The annual risk of infection may also have risen in
some of those countries most severely affected (26). Increased
funding of TB programmes has generally not kept pace with
this increasing case-load (27), and many programmes are not
achieving adequate case-detection and treatment outcomes.
Although it has been shown that ‘‘good’’ traditional TB
control measures do blunt the impact of HIV on TB (28), the
best available estimates of the incidence of TB in all African
countries show a striking correlation with estimates of adult
HIV seroprevalence (29) (Fig. 4). The burden of TB is so
closely linked to the HIV epidemic that prevention of HIV
must become a priority for TB programmes, just as TB care
and prevention should be a major concern of HIV/AIDS
programmes.
VCT for HIV as a link between control
activities for HIV and TB
Interventions to prevent HIV infection include behavioural
factors (e.g. counselling to decrease sexual risk behaviour),
biological ones (e.g. treatment of sexually transmitted infec-
tions) and the promotion of barrier methods (condoms) (30).
In industrialized countries VCT has long been an established
part of HIV programmes, and many HIV-infected people
know their HIV status. However, the vastmajority of people in
developing countries living with HIV infection do not know
that this is the case. For instance, in a random population
sample in Zambia, where at the end of 1999 the HIV
seroprevalence among the general adult population was 20%,
only 6.5% of adults had previously had an HIV test (31). VCT
is sometimes available in special groups, such as TB patients at
outpatient treatment centres in Abidjan, Coˆte d’Ivoire (32).
However, in most regions of Africa routine VCT for the
general population is rarely available (33), although there are a
few notable exceptions (34). Reasons include, on the supply
side, the high cost of VCT services, and on the demand side,
the stigma of identification as HIV-positive and the wide-
spread perception thatHIV testing offers little to the individual
who tests positive. ‘‘Why should I be tested? I will only die
sooner if I know’’ is a remark counsellors in developing
countries frequently hear (35).
From an individual’s perspective, the medical and
psychosocial support that can be offered to the majority of
people who test positive in developing countries remains
largely inadequate. However, from the public health perspec-
tive, evidence is accumulating that VCT does enable
individuals, whether they test positive or negative, to change
their behaviour in ways that should reduce rates of HIV
transmission (36, 37). An economic evaluation of a rando-
mized comparison of VCT versus health information alone in
Kenya, the Republic of Tanzania and Trinidad and Tobago
estimated that the cost of preventing a new HIV infection
(assuming that the reported behaviour change does translate
into decreasedHIV transmission) is aroundUS$ 250 (38). This
ranks VCT alongside strengthened syndromic management of
sexually transmitted infections (STIs) in primary health care as
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a cost-effective intervention to prevent HIV infection (39).
This is an important development for TB control.
VCT offers a direct entry point for more effective TB
prevention and care for HIV seropositive and seronegative
people. The majority of people infected with HIV have no
symptoms and the proportion of people who choose to be
tested for HIV is smallest among those who are without
symptoms, irrespective of their HIV status. As symptoms of
HIV-related disease develop, a few people choose to find out
whether HIV is likely to be the cause. Those with more
advanced HIV-related disease are more likely to be tested by
the clinician as part of clinical management.
Those who discover that they are not infected with HIV
have a strong motive to ensure that they remain so.
Appropriate counselling can help to translate this motivation
into behaviour change (40). Counselling also offers the
opportunity to promote more optimistic messages that may
help to destigmatize both HIV and TB.
In those who have no symptoms but are HIV
seropositive, counselling aims to prevent transmission of
HIV infection as well as to offer psychosocial support. Up to
50% of these people will subsequently develop active TB. The
incidence of TB in this group can also be reduced, at least for
some time, by preventive therapy with isoniazid (41, 42).
Counsellors need training to offer preventive therapy safely
and to ensure that their clients are diagnosed promptly if they
later develop symptoms suggestive of TB.
In those who do already have symptoms of HIV-related
disease, the challenge is to detect active cases of TB early and to
treat them effectively. Not only will early case detection
prevent ongoing transmission of TB, it may also slow the
progression of HIV infection (43).
Finally, among those with TB and advanced HIV disease,
many of whom are housebound and unable to visit their local
clinic for supervision of treatment, community-based care teams
(44–46), while caring for aspects of other HIV-related diseases,
can promote adherence to TB treatment and so prevent the
development of chronic or drug-resistant TB.
The elements of the ProTEST Initiative
Under the Initiative, the core interventions offered to people
receiving VCT for HIV are intensified TB case-finding and
isoniazid preventive treatment for those without active TB.
Pilot districts are establishing links for centres for VCT for
HIV with TB prevention and care in order to derive mutual
benefits for promoting VCT for HIV and for improving TB
control. Fig. 5 shows schematically this link between VCT and
access to interventions for HIV and TB prevention and care as
a ‘‘virtuous circle’’: promotion of VCT for HIV provides an
opportunity to offer interventions for TB prevention and care,
which themselves provide an incentive for people to undergo
VCT for HIV.
By identifying and linking the government and non-
governmental organizations currently offering support and
care for PLWHand by involving the community, the ProTEST
Initiative aims to facilitate referral and to provide the
opportunity for improving the quality of services. These
include provision of the core ProTEST interventions of TB
prevention and care, as well as an expanded range of
interventions. For example, those with more advanced HIV
disease may benefit from cotrimoxazole prophylaxis against
some bacterial causes of pneumonia and diarrhoea and their
complications (47). As antiretroviral drugs becomemuchmore
widely affordable and available in resource-poor settings, the
ProTEST Initiativemay be an opportunity to increase access to
highly active antiretroviral therapy, which has been shown to
reduce the incidence of TB and otherHIV-related infections in
other settings (48, 49).
The elements of the ProTEST Initiative are part of
comprehensive care for PLWH, which includes communic-
able disease control (particularly for TB and STIs), symptom
control and pastoral care. This requires close collaboration
between community-based care services and government or
private health facilities. Developing and making available the
‘‘continuum of care’’ (50) should encourage more people to
find out their HIV status. To meet increased demand, it will be
necessary to expand VCT services and ensure they are
accessible and user-friendly.
Openings and opportunities
The ProTEST Initiative therefore fits well with other move-
ments to encourage HIV testing, such as those linked to
programmes to deliver antiretroviral drugs to reduce transmis-
sion of HIV from mothers to their children (51). By linking
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with the ProTEST rationale, the benefits can be extended
beyond the child to the parents and family and, by reducing
transmission of HIV, TB and STIs, to the broader community.
The acceptability of VCT seems to be rising for various
reasons, which include increasing awareness of personal
responsibility as the HIV epidemic continues to devastate
families, communities and countries. The reasons for people to
get tested may be shifting. For example, the AIDS information
centre in Uganda reports an increasing proportion of their HIV
testing to be carried out for couples who are using the
information to help them plan realistically for their future (52).
The falling proportion of positive results among clients
attending testing centres after the introduction of health care
services linked to testing may also reflect a shift towards more
proactive planning.
The silence and denial that surroundHIV have been well
described (53). As more and more people choose to find out
about their HIV status, this silence and denial should lessen,
with benefits for efforts to control HIV and TB transmission.
By engaging with community organizations and encouraging
greater openness about TB and HIV, and specifically
highlighting the positive steps that can be taken to reduce
the burden of TB and HIV, the ProTEST Initiative can help to
alter the community’s perception of HIV and reduce the
associated stigma. ‘‘Normalization’’ of HIV infection should
facilitate other efforts aimed at HIV and TB prevention.
Current progress and future direction
of the ProTEST Initiative
WHO is coordinating a network of partners involved in the
ProTEST Initiative, including ministries of health of countries
bearing the dual burden of HIV and TB, international
development assistance agencies, nongovernmental organiza-
tions and academic institutions. The network will facilitate the
exchange of information and experience between partners and
provide oversight of ProTEST projects. Implementation of
the first projects is under way in Malawi, South Africa, Uganda
and Zambia.
The projects share the objective of finding out and
demonstrating what can be achieved and at what cost. The
approach is paving theway for scaling up of the comprehensive
range of interventions needed to control TB in populations
with high HIV prevalence. WHO is currently supporting the
mathematical modelling of the potential impact of a range of
interventions on the combined burden of TB and HIV. The
projects also act as a catalyst to draw national TB and HIV
programme staff together in discussions about training,
information, education, communication, service delivery, and
information management, as well as more upstream activities
such as planning and prioritization.
Recent events hold out the promise of substantially
increased aid for the priority diseases of poverty (HIV/AIDS,
TB and malaria). For example, some large-scale funding is
becoming available through the Global Fund to Fight AIDS,
Tuberculosis and Malaria. The ProTEST Initiative represents
an opportunity for financial and technical partners to
collaborate with governments and civil society in the countries
most badly affected by the HIV epidemic in substantially
increasing concerted action against HIV and TB.
Conclusions
Interventions are available to decrease the burden of HIV-
related TB. Therefore, the time is ripe for TB and HIV
programmes to collaborate in carrying out these activities as
widely as possible. The ProTEST Initiative can greatly help to
build alliances between TB and HIV programmes and to scale
up the full range of interventions to decrease the burden of
HIV-related TB. n
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Re´sume´
Comment le de´pistage volontaire du VIH peut contribuer a` la lutte antituberculeuse
Le VIH intensifie l’e´pide´mie de tuberculose, particulie`rement en
Afrique subsaharienne. Cependant, malgre´ leur relation e´pide´-
miologique e´troite, ces deux infections donnent lieu a` une re´ponse
tre`s diffe´rente de la part des services de sante´ publique. L’OMS a
e´labore´ une strate´gie visant a` re´duire la charge de la tuberculose
lie´e au VIH et comprenant des interventions dirige´es a` la fois
contre la tuberculose et contre le VIH. Le conseil et de´pistage
volontaire pour le VIH (VCT) permet de relier les activite´s des
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programmes de lutte contre le VIH et contre la tuberculose.
L’inte´reˆt du conseil et du de´pistage du VIH chez les patients
atteints de tuberculose re´side dans la possibilite´ d’adresser les
sujets VIH-positifs a` un service spe´cialise´ en vue d’un traitement et
d’un soutien approprie´s. De meˆme, les patients qui viennent en
consultation pour un VCT peuvent be´ne´ficier d’un de´pistage de la
tuberculose. Les sujets a` la fois VIH-positifs et atteints de
tuberculose active doivent eˆtre oriente´s en vue d’un traitement
antituberculeux ; ceux qui ne pre´sentent pas de tuberculose active
se verront proposer un traitement antituberculeux pre´ventif par
l’isoniazide.
Afin de rechercher de quelle fac¸on le conseil et de´pistage
volontaire pour le VIH peut contribuer a` l’adoption d’une re´ponse
plus cohe´rente face a` la tuberculose, l’OMS assure la coordination
de l’initiative ProTEST. Le nom de cette initiative renvoie a` la
promotion du de´pistage volontaire comme point de de´part pour
l’acce`s aux interventions de base que sont la recherche intensifie´e
des cas de tuberculose et le traitement pre´ventif par l’isoniazide.
D’autres interventions pourront eˆtre ajoute´es pour parvenir a` tout
un e´ventail d’interventions de pre´vention et de traitement du VIH et
de la tuberculose. Dans le cadre de l’initiative ProTEST, des districts
pilotes e´tablissent des liens entre les centres de VCT pour le VIH et
les centres de pre´vention et de traitement de la tuberculose. Cela
ouvrira la voie a` la mise en œuvre a` grande e´chelle de toute la
gamme d’interventions requise pour combattre la tuberculose dans
les re´gions de forte pre´valence du VIH.
Resumen
Las pruebas voluntarias del VIH, una posible ayuda para combatir la tuberculosis
El VIH esta´ atizando la epidemia de tuberculosis, sobre todo en el
A´frica subsahariana. Sin embargo, pese a su parentesco
epidemiolo´gico, las respuestas de salud pu´blica contra las dos
enfermedades han sido en gran medida independientes. Para
disminuir la carga de VIH relacionada con la tuberculosis, la OMS
ha formulado una estrategia que comprende intervenciones tanto
contra e´sta como contra el virus. El asesoramiento y las pruebas
voluntarias (APV) para el VIH pueden constituir un puente entre las
actividades de los programas dirigidos contra la tuberculosis y
contra el VIH. Entre los beneficios del APV para los pacientes con
tuberculosis cabe citar la derivacio´n hacia servicios de atencio´n
clı´nica y apoyo apropiados para las personas VIH-positivas.
Ana´logamente, las personas que acuden a un centro de APV
pueden beneficiarse de las actividades de cribado de la
tuberculosis: los pacientes que adema´s de ser VIH-positivos sufren
tuberculosis activa deben ser derivados para recibir tratamiento
antituberculoso; y a aquellos sin tuberculosis activa se les debe
administrar isoniazida como tratamiento preventivo contra la
tuberculosis.
A fin de determinar co´mo puede el APV para el VIH contribuir
a responder de forma ma´s coherente a la tuberculosis, la OMS esta´
coordinando la Iniciativa ProTEST, ası´ bautizada por cuanto
pretende promover las pruebas voluntarias como punto de entrada
para acceder a las intervenciones ba´sicas e intensificadas de
deteccio´n de casos y tratamiento preventivo con isoniazida. Se
pueden an˜adir otras intervenciones para proporcionar finalmente
un conjunto integral de medidas de prevencio´n y atencio´n contra el
VIH y la tuberculosis. En el marco de la Iniciativa ProTEST, diversos
distritos piloto esta´n estableciendo vı´nculos entre los centros de
APV para el VIH y la prevencio´n y atencio´n ofrecidas contra la
tuberculosis. Esto sentara´ las bases para aplicar a gran escala el
amplio conjunto de intervenciones que exige el control de la
tuberculosis en los entornos con alta prevalencia de infeccio´n por el
VIH.
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